Biomarin Pharmaceutical Stock News

NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin's leadership team provided an overview of the company's new corporate strategy to deliver sustained value creation and introduced longer-term Total Revenue and Non-GAAP Operating Margi...

NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York.

SAN RAFAEL, Calif. , Aug. 29, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024, at 7:45 AM PT / 10:45 AM ET in New York, NY.

BioMarin Pharmaceutical will reduce its global workforce by about 225 employees, a filing showed on Wednesday.

BioMarin Pharmaceutical Inc. sales of Voxzogo had increased by 62% to $184 million in Q2 of 2024, compared to the same period in 2023. Potential to eventually expand the use of Voxzogo towards other indications like hypochondroplasia and idiopathic short stature. Data from the phase 1/2 study, using BMN351 for the treatment of patients with DMD amenable to exon 51 skipping, expected by the end ...

Greg Friberg, M.D., Appointed EVP, Chief Research & Development Officer as Hank Fuchs, M.D.

- Event to be webcast live and a replay will be available SAN RAFAEL, Calif. , Aug. 19, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an Investor Day with financial analysts and institutional investors on Wednesday, September 4, 2024, in New York City from 10:30 am to 1:00 pm Eastern Time.

Revenue for Q2 2024 totaled $712 million, a 20% year-over-year increase. Management raised full-year 2024 guidance, reflecting the company's optimistic outlook.